New horizons in high-risk AML

Leading AML experts discuss novel therapeutic approaches and clinical trial data for high-risk AML. Discover more by exploring exclusive interviews and roundtable discussions.

Watch Guillermo Garcia-Manero, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, highlight the issues around treating acute myeloid leukemia (AML) in the elderly and potential approaches to combat these. While hypomethylating agents are a mainstay therapy in this patient group, it is nevertheless important to treat each elderly patient on a case by case basis. Dr Garcia-Manero presents some of these options, which include chemotherapy, as well as novel compounds that target specific mutations.

Alternative approaches to AML in the over 70s

Novel targets and compounds for AML in the elderly

Exploring future combinations with immunotherapy in AML

HDAC inhibitor-hypomethylating agent combinations in elderly AML patients

Factors to consider in allogeneic transplant in AML

The age-old discussion: managing AML in the elderly

Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, chairs a dynamic discussion with fellow AML specialists, Farhad Ravandi, MD, and Naval Daver, MD, both from the University of Texas MD Anderson Cancer Center, Houston, TX. Together they explore different perspectives on the treatment of AML in older adults and evaluate future treatment options. Aspects discussed by the physicians include whether or not to consider transplant, if and how much chemotherapy can be administered to their older patients before hypomethylating agents are prescribed, inclusion of patients in clinical trials in order to gain access to novel treatments, and how current studies with HDAC inhibitors could benefit their patients in the future.

HDAC inhibitor studies may increase treatment options in AML

Intensive chemotherapy, low-intensity therapy, or transplant for AML?

Current experience with novel agents and combinations in elderly AML

Debate on novel therapies for elderly AML and MRD assessment